Eribulin

Acknowledgment: Data collected from https://www.totalpatentone.com/

 

DateAbstractPatent Application
2009-03-30The present invention provides a novel liposome composition containing eribulin or its pharma¬cologically permissible salt, and its method of manufacture.IN6850DELNP2011A
2010-01-26In general the invention features compounds useful for the synthesis of analogs of halichondrin B such as eribulin or pharmaceutically acceptable salts thereof e.g. eribulin mesylate. Exemplary compounds are of formula (I) (II) or (III).IN7310CHENP2012A
2011-03-18The invention provides methods for predicting the efficacy of eribulin an analog thereof or a pharmaceutically acceptable salt thereof (e.g. eribulin mesylate) in the treatment of a subject suffering from breast cancer by determining the level of particular biomarkers in a sample derived from the subject.IN8212DELNP2013A
2011-04-28The present invention provides methods for producing eribulin intermediates useful for the synthesis of eribulin or pharmaceutically acceptable salts thereof e.g. eribulin mesylate using microreactors.IN8197CHENP2013A
2013-06-26The invention provides methods and compositions for use in treating diseases associated with excessive cellular proliferation such as cancer.IN201647001874A
2013-11-04The invention provides methods for the synthesis of eribulin or a pharmaceutically acceptable salt thereof (e.g. eribulin mesylate) through a macrocyclization strategy. The macrocyclization strategy of the present invention involves subjecting a non macrocyclic intermediate to a carbon carbon bond forming reaction (e.g. an olefination reaction (e.g. Horner Wadsworth Emmons olefination) Dieckmann reaction catalytic Ring Closing Olefin Metathesis or Nozaki Hiyama Kishi reaction) to afford a macrocyclic intermediate. The invention also provides compounds useful as intermediates in the synthesis of eribulin or a pharmaceutically acceptable salt thereof and methods for preparing the same.IN201647018612A
2013-12-06In general the present invention features improved methods useful for the synthesis of analogs of halichondrin B such as eribulin and pharmaceutically acceptable salts thereof (e.g. eribulin mesylate).IN201647018392A
2014-03-03Methods for treating cancer (e.g. breast cancer lung cancer pancreatic cancer primitive neuroectodermal tumors lung cancer ovaria cancer endometrial cancer pharyngeal cancer esophageal cancer and sarcoma) in a subject (such as an human patient) in need thereof by administering eribulin (e.g. eribulin mesylate i.e. E7389 Halaven) in combination with one or more mammalian target of rapamycin (mTOR) inhibitors (e.g. everolimus ridaforolimus and temsirolimus) and kits therefor are provided.IN201647032920A
2014-05-28The invention features methods and kits for use in treating cancer in a patient in need thereof by administering eribulin or a pharmaceutically acceptable salt thereof (e.g. eribulin mesylate) prior to a second agent.IN201647044265A
2014-08-27123 Provided is a method for producing eribulin and a salt thereof efficiently and at high yield by a method for producing a compound represented by formula (II) the method including a step for stirring a reactant in the presence of manganese powder and a chromium compound using a homogenizer. (In the formula PG PG and PG each independently represent hydroxyl protecting groups.)IN201747005346A
2016-02-12The invention relates to methods and intermediates useful in the synthesis of eribulin.IN201847033256A
2016-03-02Linker toxins and antibody-drug conjugates that bind to human oncology antigen targets such as folate receptor alpha and/or provide anti-tubulin drug activity are disclosed. The linker toxins and antibody-drug conjugates comprise an eribulin drug moiety and can be internalized into target antigen-expressing cells. The disclosure further relates to methods and compositions for use in the treatment of cancer by administering the antibody-drug conjugates provided herein.IN201817036072A